Consolidated Statements of Cash Flows (unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (40,080,274)	$ (51,261,694)
(Gain) loss on disposal of fixed assets		(19,195)
Change in value of derivatives	(346,411)	(2,551,116)
Acquired in-process research and development		10,142,786
Stock-based compensation	4,797,182	4,219,935
Depreciation and amortization	1,598,261	739,598
Amortization of note premiums	179,460	668,364
Changes in operating assets and liabilities:
Prepaid expenses and Other Current Assets	(641,840)	(3,502,618)
Accounts payable	2,510,792	2,402,381
Accrued expenses	(4,103,354)	(1,442,450)
Other	190,280	34,425
NET CASH USED IN OPERATING ACTIVITIES	(35,895,904)	(40,569,584)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(500,634)	(852,063)
Proceeds from sale of fixed assets		500
Proceeds from sale of marketable securities	6,200,000	12,150,774
Cash paid for acquisitions		(7,000,000)
NET CASH PROVIDED BY INVESTING ACTIVITIES	5,699,366	4,299,211
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on capital leases and notes payable	(108,326)	(106,554)
Payments of taxes for net share settled restricted stock unit issuances	(634,187)
Proceeds from the exercise of warrants and stock options	25,544	313,618
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	(716,969)	207,064
NET INCREASE (DECREASE) IN CASH	(30,913,507)	(36,063,309)
CASH AT BEGINNING OF PERIOD	81,214,354	132,510,610
CASH AT END OF PERIOD	50,300,847	96,447,301
Supplementary disclosures:
Interest paid	(5,797)	(7,655)
Income Tax Credits Refunded	1,365,288
Income Taxes Paid	$ (2,400)	(2,400)
Common Stock issued to Novartis for asset acquisition		$ 25,000,000